Clinical trial / 2013
Bioavailable curcumin was safely administered alongside chemotherapy in biliary and pancreatic cancer.
Sixteen pancreatic or biliary tract cancer patients who had failed standard chemotherapy received daily oral Theracurmin at either 200 mg (n = 10) or 400 mg (n = 6) with gemcitabine-based chemotherapy. Median peak plasma curcumin concentrations reached 324 ng/mL at the lower dose and 440 ng/mL at the higher dose. No unexpected adverse events occurred, and three individuals safely continued Theracurmin for more than 9 months.
- Study type
- Phase I clinical trial
- Who was studied
- 16 pancreatic or biliary tract cancer patients who failed standard chemotherapy
- What was measured
- Safety, pharmacokinetics, and tolerability
THE PAPER
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.
Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S, Murakami Y, Imaizumi A, Chiba T, Nishihira J, Shibata H. Cancer Chemother Pharmacol, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.